Peringatan Keamanan

Age, gender, and race do not significantly affect solriamfetol pharmacokinetics and no dose adjustments were made in clinical trials for patients over 65 yearsFDA Label.

Patients with renal failure experience increases in half life between 1.2 and 3.9 times that in healthy patientsFDA Label. 21% of solriamfetol was removed by hemodialysis, however time to peak concentration was not affectedFDA Label.

Solriamfetol is not expected to lead to adverse effects in pregnancyFDA Label. Maternal and fetal toxicity was seen in animal studies at ?4 and 5 times the maximum recommended human dose and teratogenicity was seen at 19 and ?5 times the maximum recommended human doseFDA Label.

Breastfed infants should be monitored for adverse reactions such as agitation, insomnia, anorexia, and reduced weight gain as solriamfetol is present in breast milkFDA Label. However, there is no currently available data on the effect of solriamfetol in breast milk on breast fed inantsFDA Label.

Safety and effectiveness of solriamfetol in pediatric patients has not been established in clinical studiesFDA Label.

Solriamfetol does not display different safety or effectiveness in geriatric populationsFDA Label.

Dosage adjustments are recommended for patients with eGFR <60mL/min/1.73m^2 and solriamfetol is not recommended for patients with an eGFR <15mL/min/1.73m^2FDA Label.

Solriamfetol

DB14754

small molecule approved

Deskripsi

Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apneaFDA Label. Solriamfetol was given FDA approval in 2019FDA Label.

Struktur Molekul 2D

Berat 194.234
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 7.1 hours[FDA Label]. Other studies have found the mean half life to be 6.1 ± 1.2 hours in fasted subjects and 5.9 ± 1.2 hours in fed subjects[A176744].
Volume Distribusi 199L[FDA Label]. Other studies have found the volume of distribution to be 158.2L ± 37.3L in fasted subjects and 159.8L ± 38.9L in fed subjects[A176744].
Klirens (Clearance) Renal clearance is 18.2L/h and total clearance is 19.5L/h[FDA Label]. Other studies have found clearance to be 18.4 ± 4.2L/h in fasted subjects and 18.8 ± 4.2L/h in fed subjects[A176744].

Absorpsi

Oral bioavailability of solriamfetol is approximately 95%FDA Label. Peak plasma concentration is reached in 2 hours (with a range of 1.25 to 3 hours) in fasted patientsFDA Label. When solriamfetol is taken with a high fat meal, the time to peak plasma concentration increases to 3 hoursFDA Label.

Metabolisme

Solriamfetol does not undergo significant metabolism in humans, though less than 1% of solriamfetol is metabolized to N-acetyl solriamfetolFDA LabelA176516.

Rute Eliminasi

95% of solriamfetol is recovered in urine unchanged by metabolismFDA Label. Less than 1% of solriamfetol is recovered as N-acetyl solriamfetolFDA LabelA176516.

Interaksi Makanan

1 Data
  • 1. Take with or without food.

Interaksi Obat

1641 Data
Valsartan Solriamfetol may decrease the antihypertensive activities of Valsartan.
Ramipril Solriamfetol may decrease the antihypertensive activities of Ramipril.
Esmolol Solriamfetol may decrease the antihypertensive activities of Esmolol.
Betaxolol Solriamfetol may decrease the antihypertensive activities of Betaxolol.
Remikiren Solriamfetol may decrease the antihypertensive activities of Remikiren.
Guanadrel Solriamfetol may decrease the antihypertensive activities of Guanadrel.
Olmesartan Solriamfetol may decrease the antihypertensive activities of Olmesartan.
Atenolol Solriamfetol may decrease the antihypertensive activities of Atenolol.
Diltiazem Solriamfetol may decrease the antihypertensive activities of Diltiazem.
Minoxidil Solriamfetol may decrease the antihypertensive activities of Minoxidil.
Treprostinil Solriamfetol may decrease the antihypertensive activities of Treprostinil.
Amlodipine Solriamfetol may decrease the antihypertensive activities of Amlodipine.
Nimodipine Solriamfetol may decrease the antihypertensive activities of Nimodipine.
Prazosin Solriamfetol may decrease the antihypertensive activities of Prazosin.
Trandolapril Solriamfetol may decrease the antihypertensive activities of Trandolapril.
Lercanidipine Solriamfetol may decrease the antihypertensive activities of Lercanidipine.
Benazepril Solriamfetol may decrease the antihypertensive activities of Benazepril.
Bosentan Solriamfetol may decrease the antihypertensive activities of Bosentan.
Enalapril Solriamfetol may decrease the antihypertensive activities of Enalapril.
Doxazosin Solriamfetol may decrease the antihypertensive activities of Doxazosin.
Candoxatril Solriamfetol may decrease the antihypertensive activities of Candoxatril.
Losartan Solriamfetol may decrease the antihypertensive activities of Losartan.
Moexipril Solriamfetol may decrease the antihypertensive activities of Moexipril.
Nitroglycerin Solriamfetol may decrease the antihypertensive activities of Nitroglycerin.
Cryptenamine Solriamfetol may decrease the antihypertensive activities of Cryptenamine.
Candesartan cilexetil Solriamfetol may decrease the antihypertensive activities of Candesartan cilexetil.
Eprosartan Solriamfetol may decrease the antihypertensive activities of Eprosartan.
Quinapril Solriamfetol may decrease the antihypertensive activities of Quinapril.
Telmisartan Solriamfetol may decrease the antihypertensive activities of Telmisartan.
Felodipine Solriamfetol may decrease the antihypertensive activities of Felodipine.
Irbesartan Solriamfetol may decrease the antihypertensive activities of Irbesartan.
Nitrendipine Solriamfetol may decrease the antihypertensive activities of Nitrendipine.
Deserpidine Solriamfetol may decrease the antihypertensive activities of Deserpidine.
Pentolinium Solriamfetol may decrease the antihypertensive activities of Pentolinium.
Trimethaphan Solriamfetol may decrease the antihypertensive activities of Trimethaphan.
Carvedilol Solriamfetol may decrease the antihypertensive activities of Carvedilol.
Bretylium Solriamfetol may decrease the antihypertensive activities of Bretylium.
Terazosin Solriamfetol may decrease the antihypertensive activities of Terazosin.
Acebutolol Solriamfetol may decrease the antihypertensive activities of Acebutolol.
Captopril Solriamfetol may decrease the antihypertensive activities of Captopril.
Bepridil Solriamfetol may decrease the antihypertensive activities of Bepridil.
Bevantolol Solriamfetol may decrease the antihypertensive activities of Bevantolol.
Practolol Solriamfetol may decrease the antihypertensive activities of Practolol.
Cilazapril Solriamfetol may decrease the antihypertensive activities of Cilazapril.
Saprisartan Solriamfetol may decrease the antihypertensive activities of Saprisartan.
Spirapril Solriamfetol may decrease the antihypertensive activities of Spirapril.
Mibefradil Solriamfetol may decrease the antihypertensive activities of Mibefradil.
Dexpropranolol Solriamfetol may decrease the antihypertensive activities of Dexpropranolol.
Debrisoquine Solriamfetol may decrease the antihypertensive activities of Debrisoquine.
Celiprolol Solriamfetol may decrease the antihypertensive activities of Celiprolol.
Nebivolol Solriamfetol may decrease the antihypertensive activities of Nebivolol.
Sitaxentan Solriamfetol may decrease the antihypertensive activities of Sitaxentan.
Ambrisentan Solriamfetol may decrease the antihypertensive activities of Ambrisentan.
Diethylnorspermine Solriamfetol may decrease the antihypertensive activities of Diethylnorspermine.
Nilvadipine Solriamfetol may decrease the antihypertensive activities of Nilvadipine.
Pinacidil Solriamfetol may decrease the antihypertensive activities of Pinacidil.
Bupranolol Solriamfetol may decrease the antihypertensive activities of Bupranolol.
Temocapril Solriamfetol may decrease the antihypertensive activities of Temocapril.
Riociguat Solriamfetol may decrease the antihypertensive activities of Riociguat.
Indenolol Solriamfetol may decrease the antihypertensive activities of Indenolol.
Aliskiren Solriamfetol may decrease the antihypertensive activities of Aliskiren.
Trimazosin Solriamfetol may decrease the antihypertensive activities of Trimazosin.
Lacidipine Solriamfetol may decrease the antihypertensive activities of Lacidipine.
Manidipine Solriamfetol may decrease the antihypertensive activities of Manidipine.
Niguldipine Solriamfetol may decrease the antihypertensive activities of Niguldipine.
Rauwolfia serpentina root Solriamfetol may decrease the antihypertensive activities of Rauwolfia serpentina root.
Selexipag Solriamfetol may decrease the antihypertensive activities of Selexipag.
Angiotensin 1-7 Solriamfetol may decrease the antihypertensive activities of Angiotensin 1-7.
Talinolol Solriamfetol may decrease the antihypertensive activities of Talinolol.
Imidapril Solriamfetol may decrease the antihypertensive activities of Imidapril.
BQ-123 Solriamfetol may decrease the antihypertensive activities of BQ-123.
Landiolol Solriamfetol may decrease the antihypertensive activities of Landiolol.
Dihydralazine Solriamfetol may decrease the antihypertensive activities of Dihydralazine.
Zofenopril Solriamfetol may decrease the antihypertensive activities of Zofenopril.
Guanoxan Solriamfetol may decrease the antihypertensive activities of Guanoxan.
Delapril Solriamfetol may decrease the antihypertensive activities of Delapril.
Vincamine Solriamfetol may decrease the antihypertensive activities of Vincamine.
Linsidomine Solriamfetol may decrease the antihypertensive activities of Linsidomine.
Guanoxabenz Solriamfetol may decrease the antihypertensive activities of Guanoxabenz.
Tolonidine Solriamfetol may decrease the antihypertensive activities of Tolonidine.
Endralazine Solriamfetol may decrease the antihypertensive activities of Endralazine.
Esatenolol Solriamfetol may decrease the antihypertensive activities of Esatenolol.
Cadralazine Solriamfetol may decrease the antihypertensive activities of Cadralazine.
Cloranolol Solriamfetol may decrease the antihypertensive activities of Cloranolol.
Bietaserpine Solriamfetol may decrease the antihypertensive activities of Bietaserpine.
Guanazodine Solriamfetol may decrease the antihypertensive activities of Guanazodine.
Methoserpidine Solriamfetol may decrease the antihypertensive activities of Methoserpidine.
Epanolol Solriamfetol may decrease the antihypertensive activities of Epanolol.
Guanoclor Solriamfetol may decrease the antihypertensive activities of Guanoclor.
Candesartan Solriamfetol may decrease the antihypertensive activities of Candesartan.
Dexniguldipine Solriamfetol may decrease the antihypertensive activities of Dexniguldipine.
Tocopherylquinone Solriamfetol may decrease the antihypertensive activities of Tocopherylquinone.
Benazeprilat Solriamfetol may decrease the antihypertensive activities of Benazeprilat.
Fosinoprilat Solriamfetol may decrease the antihypertensive activities of Fosinoprilat.
Ramiprilat Solriamfetol may decrease the antihypertensive activities of Ramiprilat.
Perindoprilat Solriamfetol may decrease the antihypertensive activities of Perindoprilat.
Quinaprilat Solriamfetol may decrease the antihypertensive activities of Quinaprilat.
Levamlodipine Solriamfetol may decrease the antihypertensive activities of Levamlodipine.
Azilsartan medoxomil Solriamfetol may decrease the antihypertensive activities of Azilsartan medoxomil.
Diazoxide Solriamfetol may decrease the antihypertensive activities of Diazoxide.

Target Protein

Sodium-dependent dopamine transporter SLC6A3
Sodium-dependent noradrenaline transporter SLC6A2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 12502022
    Amsterdam JD, Brunswick DJ, Hundert M: A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A--a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec;26(7-8):1333-8.
  • PMID: 29891587
    Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A: Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. doi: 10.1124/jpet.118.248120. Epub 2018 Jun 11.
  • PMID: 30521757
    Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP: Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3): A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Dec 6. doi: 10.1164/rccm.201806-1100OC.
  • PMID: 30598342
    Zomorodi K, Kankam M, Lu Y: A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food. Clin Ther. 2019 Feb;41(2):196-204. doi: 10.1016/j.clinthera.2018.12.001. Epub 2018 Dec 28.

Contoh Produk & Brand

Produk: 16 • International brands: 0
Produk
  • Sunosi
    Tablet, film coated • 75 mg/1 • Oral • US • Approved
  • Sunosi
    Tablet, film coated • 150 mg/1 • Oral • US • Approved
  • Sunosi
    Tablet • 75 mg • Oral • Canada • Approved
  • Sunosi
    Tablet • 150 mg • Oral • Canada • Approved
  • Sunosi
    Tablet, film coated • 75 mg/1 • Oral • US • Approved
  • Sunosi
    Tablet, film coated • 150 mg/1 • Oral • US • Approved
  • Sunosi
    Tablet, film coated • 75 mg • Oral • EU • Approved
  • Sunosi
    Tablet, film coated • 75 mg • Oral • EU • Approved
Menampilkan 8 dari 16 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul